

Correction: Preclinical Assessment of FHIT Gene Replacement Therapy in Human Leukemia Using a Chimeric Adenovirus, Ad5/F35

In this article (Clin Cancer Res 2006;12:3494–501), which was published in the June 1, 2006, issue of *Clinical Cancer Research* (1), a reader pointed out what appeared to be potential image reuse in several figures. Specifically, the FHIT reexpression in the different cell lines presented in the blot for Fig. 1B appears to be duplicated in Fig. 3A. In addition, FHIT reexpression in the "K562" and "RS4;11" lanes in Fig. 3A appears to be identical. The authors admitted administrative error and provided original films for the above-mentioned figures, as well as an updated version of Fig. 4A, which correctly displays the last lane as empty vector (EV). Corrected sections of Figs. 1B, 3A, and 4A are below. The results and conclusions put forth in this article remain unchanged. The authors regret these errors.



Figure 1B.

FHIT expression in Ad5/F35-FHIT-infected cell lines by Western blot analysis as indicated.




Figure 3A.

Western blot analysis showing FHIT ectopic expression in K562, Molt-3, and RS4;11 cells infected with Ad5/F35-FHIT. GAPDH levels are showing equal loading for each cell line.




Figure 4A.

Expression of TP53 mRNA in K562 TP53-stable clones by RT-PCR. RT-PCR products in K562 empty vector colonies (lanes 1, 2, and 10), K562 p53-expressing stable colonies (lanes 3–9).

Reference

- Pichiorri F, Trapasso F, Palumbo T, Aqeilan RI, Drusco A, Blaser BW, et al. Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35. Clin Cancer Res 2006;12:3494–501.

Published OnlineFirst November 17, 2016.

doi: 10.1158/1078-0432.CCR-16-2893

©2016 American Association for Cancer Research.

Clinical Cancer Research

Correction: Preclinical Assessment of FHIT Gene Replacement Therapy in Human Leukemia Using a Chimeric Adenovirus, Ad5/F35

Clin Cancer Res Published OnlineFirst November 17, 2016.

Updated version Access the most recent version of this article at:
doi:[10.1158/1078-0432.CCR-16-2893](https://doi.org/10.1158/1078-0432.CCR-16-2893)

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/early/2016/11/17/1078-0432.CCR-16-2893>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.